ILMN * Stock Overview Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Illumina, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Illumina Historical stock prices Current Share Price US$2,890.00 52 Week High US$3,094.82 52 Week Low US$1,745.40 Beta 1.11 1 Month Change -6.62% 3 Month Change 11.03% 1 Year Change 22.34% 3 Year Change -63.61% 5 Year Change -52.09% Change since IPO 49.12%
Recent News & Updates
Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio Nov 20
Third quarter 2024 earnings released: EPS: US$4.43 (vs US$4.77 loss in 3Q 2023) Nov 06
Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024 Nov 06 Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024
Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting Oct 31
Illumina, Inc. Introduces the MiSeq i100 Series Oct 10 See more updates
Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio Nov 20
Third quarter 2024 earnings released: EPS: US$4.43 (vs US$4.77 loss in 3Q 2023) Nov 06
Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024 Nov 06 Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024
Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting Oct 31
Illumina, Inc. Introduces the MiSeq i100 Series Oct 10
Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 08
Illumina, Inc. Announces Executive Changes Oct 04
European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL Sep 03
Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies Aug 28
Second quarter 2024 earnings released: US$12.50 loss per share (vs US$1.48 loss in 2Q 2023) Aug 07 Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024
Illumina Launches New Oncology Menu for NovaSeq X Series Customers Aug 06
Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc. Jul 11
Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc. Jul 10
Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jun 25
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value Jun 24 Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost
Illumina, Inc. Appoints Anna Richo to its Board of Directors May 22
Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024 May 03 Illumina, Inc. Announces Chief Financial Officer Changes Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024
CEO & Director recently bought Mex$17m worth of stock Feb 27
Full year 2023 earnings released: US$7.35 loss per share (vs US$28.05 loss in FY 2022) Feb 21 Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024
Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc Jan 02
Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc Dec 19
Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys Dec 06
Third quarter 2023 earnings released: US$4.77 loss per share (vs US$24.31 loss in 3Q 2022) Nov 17
New major risk - Revenue and earnings growth Nov 12 Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc
Third quarter 2023 earnings released: US$4.77 loss per share (vs US$24.31 loss in 3Q 2022) Nov 11
Carl Icahn Accuses Board and Ex-CEO of Illumina Inc Oct 25
Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties Oct 20
EU Orders Illumina to Sell Cancer Testing Firm Grail Oct 13
Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 06
Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team Sep 22
Illumina, Inc. Announces Chief Executive Officer Changes Sep 07
Second quarter 2023 earnings released: US$1.48 loss per share (vs US$3.41 loss in 2Q 2022) Aug 11 Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023
Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research Aug 03
Chief Commercial Officer recently sold Mex$1.6m worth of stock Jul 31
Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 21
Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery Jul 12
Chief Commercial Officer recently sold Mex$1.7m worth of stock Jun 29 Illumina, Inc. Announces CEO Changes
Illumina, Inc. Announces Board Changes Jun 03
Illumina Unveils AI Software to Predict Disease-Causing Genetic Mutations in Patients Jun 02
Chief Commercial Officer recently sold Mex$19m worth of stock May 27 Illumina, Inc. Announces Board Changes May 26
First quarter 2023 earnings released: EPS: US$0.019 (vs US$0.55 in 1Q 2022) May 08
Insufficient new directors May 03
First quarter 2023 earnings released: EPS: US$0.019 (vs US$0.55 in 1Q 2022) Apr 27
Insufficient new directors Apr 20
Insufficient new directors Mar 03
Full year 2022 earnings released: US$28.05 loss per share (vs US$5.08 profit in FY 2021) Feb 09
Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Feb 08
Illumina Appoints Joydeep Goswami as Chief Financial Officer Feb 02 Illumina, Inc. to Report Q4, 2022 Results on Feb 07, 2023
Insufficient new directors Dec 22
Insufficient new directors Dec 02
Now 21% undervalued Nov 19
Insufficient new directors Nov 16 Illumina Provides Earnings Guidance for the Full Year of 2022
Illumina Introduces New Research Test to Address One of the Most Common Infections in the United States Nov 02
Illumina, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 07
Illumina, Inc. Appoints Scott Ericksen as Vice President and Chief Accounting Officer, Effective as of October 16, 2022 Oct 01
Illumina, Inc. Unveils NovaSeq X Series to Rapidly Accelerate Genomic Discoveries and Improve Human Health Sep 30
Insufficient new directors Sep 21
Illumina, Inc. Announces Resignation of Jose Torres as Chief Accounting Officer, Effective as of October 14, 2022 Sep 17 Illumina Intends to Appeal EC's Decision in Grail Deal
Insufficient new directors Sep 01
Second quarter 2022 earnings released: US$3.41 loss per share (vs US$1.27 profit in 2Q 2021) Aug 12
Now 27% undervalued after recent price drop Aug 12
Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Aug 12
Illumina Unveils Its Most Accurate and Comprehensive Secondary Analysis Platform, Boosting Lab Capabilities Jul 28 Illumina, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Illumina, Inc.(NasdaqGS:ILMN) dropped from Russell 1000 Growth-Defensive Index
Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome Jun 23
Investor sentiment deteriorated over the past week Jun 14
Illumina, Inc. Announces Chief Financial Officer Changes Jun 10 Shareholder Returns ILMN * MX Life Sciences MX Market 7D 0% 0% 0% 1Y 22.3% 0% 0%
See full shareholder returns
Return vs Market: ILMN * exceeded the MX Market which returned -14.1% over the past year.
Price Volatility Is ILMN *'s price volatile compared to industry and market? ILMN * volatility ILMN * Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: ILMN *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine ILMN *'s volatility change over the past year.
About the Company Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Show more Illumina, Inc. Fundamentals Summary How do Illumina's earnings and revenue compare to its market cap? ILMN * fundamental statistics Market cap Mex$433.04b Earnings (TTM ) -Mex$31.82b Revenue (TTM ) Mex$88.12b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ILMN * income statement (TTM ) Revenue US$4.39b Cost of Revenue US$1.42b Gross Profit US$2.97b Other Expenses US$4.55b Earnings -US$1.58b
Last Reported Earnings
Sep 29, 2024
Earnings per share (EPS) -9.99 Gross Margin 67.61% Net Profit Margin -36.10% Debt/Equity Ratio 93.6%
How did ILMN * perform over the long term?
See historical performance and comparison Dividends
1.9% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 05:06 End of Day Share Price 2024/11/26 00:00 Earnings 2024/09/29 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Illumina, Inc. is covered by 58 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company James Francis Mainwaring Atlantic Equities LLP Catherine Ramsey Schulte Baird
Show 55 more analysts 
